Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome
- Conditions
- Cushing's Syndrome
- Registration Number
- NCT02663609
- Lead Sponsor
- Corcept Therapeutics
- Brief Summary
Chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome.
- Detailed Description
A retrospective, multi-center, chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome. Treatment with Korlym® will be a minimum 3 months in duration with follow-up of a minimum 3 months. Only sites that have been identified to have patients appropriate for this protocol will be invited to participate.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
- Diagnosed with ACTH independent endogenous Cushing's Syndrome
- Available adrenal imaging prior to being treated with Korlym®
- Treated with Korlym® and followed for at least 3 months (follow-up data should be available)
- Diagnosed with adrenocortical carcinoma
- Participant in any clinical trial(s) during the observational period
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Drug Utilization Patterns as assessed by chart review up to 4 years The retrospective review would analyze the drug utilization patterns of patients treated with Korlym
- Secondary Outcome Measures
Name Time Method Clinical Outcomes as assessed by chart review up to 4 years The retrospective review would analyze outcomes measures (vitals, clinical assessments, etc) in patients treated with Korlym